117 related articles for article (PubMed ID: 21737629)
1. Response of thyroglobulin to radioiodine therapy in thyroglobulin-elevated negative iodine scintigraphy (TENIS) syndrome.
Sinha P; Conrad GR; West HC
Anticancer Res; 2011 Jun; 31(6):2109-12. PubMed ID: 21737629
[TBL] [Abstract][Full Text] [Related]
2. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
Chao M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
[TBL] [Abstract][Full Text] [Related]
3. Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?
Schaap J; Eustatia-Rutten CF; Stokkel M; Links TP; Diamant M; van der Velde EA; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2002 Jul; 57(1):117-24. PubMed ID: 12100079
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
[TBL] [Abstract][Full Text] [Related]
5. Outcome of patients with differentiated thyroid cancer treated with empirical radioiodine therapy on the basis of Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) syndrome without structural disease: a retrospective cohort study.
Yuan L; Wang J; Pan L; Feng H; Chen P; Luo J; Xie J; Xiong X; Wu J; Ouyang W
Ann Nucl Med; 2023 Jan; 37(1):18-25. PubMed ID: 36318362
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
Zakani A; Saghari M; Eftekhari M; Fard-Esfahani A; Fallahi B; Esmaili J; Assadi M
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer.
Ha S; Oh SW; Kim YK; Koo do H; Jung YH; Yi KH; Chung JK
J Korean Med Sci; 2015 Jul; 30(7):876-81. PubMed ID: 26130949
[TBL] [Abstract][Full Text] [Related]
9. Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases.
Kabasakal L; Selçuk NA; Shafipour H; Ozmen O; Onsel C; Uslu I
Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1500-4. PubMed ID: 15232654
[TBL] [Abstract][Full Text] [Related]
10. Unusual case of well-differentiated papillary thyroid carcinoma lacking thyroglobulin expression while still concentrating radioiodine.
Singh B; Bollmann R; Ahmadzadehfar H; Biersack HJ; Ezziddin S
Br J Radiol; 2006 Sep; 79(945):e84-7. PubMed ID: 16940367
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
[TBL] [Abstract][Full Text] [Related]
12. 131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated?
McDougall IR
Thyroid; 1997 Aug; 7(4):669-72. PubMed ID: 9292959
[TBL] [Abstract][Full Text] [Related]
13. Value of thyroglobulin to 131I uptake ratio in selection of initial therapy dose of 131I in patients with differentiated thyroid carcinoma.
Zerva B; Koutsikos J; Palestidis C; Kounadi E; Gerali S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):348-54. PubMed ID: 17043633
[TBL] [Abstract][Full Text] [Related]
14. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.
Pacini F; Agate L; Elisei R; Capezzone M; Ceccarelli C; Lippi F; Molinaro E; Pinchera A
J Clin Endocrinol Metab; 2001 Sep; 86(9):4092-7. PubMed ID: 11549631
[TBL] [Abstract][Full Text] [Related]
15. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
Ma C; Xie J; Kuang A
J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
[TBL] [Abstract][Full Text] [Related]
16. Early sequential changes in serum thyroglobulin after radioiodine ablation for thyroid cancer: possible clinical implications for recombinant human thyrotropin-aided therapy.
Taïeb D; Lussato D; Guedj E; Roux F; Mundler O
Thyroid; 2006 Feb; 16(2):177-9. PubMed ID: 16676403
[TBL] [Abstract][Full Text] [Related]
17. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
Kim WG; Ryu JS; Kim EY; Lee JH; Baek JH; Yoon JH; Hong SJ; Kim ES; Kim TY; Kim WB; Shong YK
J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
[TBL] [Abstract][Full Text] [Related]
18. The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome.
Silberstein EB
Semin Nucl Med; 2011 Mar; 41(2):113-20. PubMed ID: 21272685
[TBL] [Abstract][Full Text] [Related]
19. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
20. The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial ¹³¹I therapy.
van Dijk D; Plukker JT; van der Horst-Schrivers AN; Jansen L; Brouwers AH; Muller-Kobold A; Sluiter WJ; Links TP
Clin Endocrinol (Oxf); 2011 Jan; 74(1):104-10. PubMed ID: 21039721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
